Omeros ROE 2009-2019 | OMER
Current and historical return on equity (ROE) values for Omeros (OMER) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Omeros ROE for the three months ending March 31, 2019 was 0.00%.
| Omeros ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2019-03-31 | $-0.12B | $-0.12B | 132.24% |
| 2018-12-31 | $-0.13B | $-0.10B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.09B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.06B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.03B | 348.72% |
| 2017-12-31 | $-0.05B | $-0.00B | 218.56% |
| 2017-09-30 | $-0.06B | $0.01B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.06B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.05B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.02B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.05B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.04B | 458.82% |
| 2015-12-31 | $-0.08B | $-0.03B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.04B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.03B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.02B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $-0.00B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.02B | 388.89% |
| 2012-03-31 | $-0.03B | $-0.01B | 2480.00% |
| 2011-12-31 | $-0.03B | $-0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.00B | -212.24% |
| 2011-06-30 | $-0.03B | $0.01B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.02B | -109.09% |
| 2010-09-30 | $-0.03B | $0.02B | -87.22% |
| 2010-06-30 | $-0.03B | $0.03B | -104.17% |
| 2010-03-31 | $-0.02B | $0.04B | -139.39% |
| 2009-12-31 | $-0.02B | $0.04B | -289.66% |
| 2009-06-30 | $-0.02B | $0.00B | inf% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.719B | $0.030B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $154.348B | 29.07 |
| Medtronic (MDT) | Ireland | $135.189B | 19.31 |
| Stryker (SYK) | United States | $77.613B | 27.70 |
| Boston Scientific (BSX) | United States | $58.755B | 28.17 |
| Baxter (BAX) | United States | $42.395B | 26.72 |
| EssilorLuxottica Societe Anonyme (ESLOY) | France | $29.186B | 0.00 |
| Coloplast (CLPBY) | Denmark | $25.855B | 41.28 |
| Lonza Group Ag (LZAGY) | Switzerland | $25.565B | 0.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.282B | 16.24 |
| Terumo (TRUMY) | Japan | $22.330B | 25.68 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $18.881B | 0.00 |
| ResMed (RMD) | United States | $17.703B | 33.82 |
| Sunny Optical Technology (SNPTF) | China | $12.345B | 0.00 |
| Canopy Growth (CGC) | Canada | $12.272B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.392B | 49.79 |
| William Demant Holdings (WILYY) | Denmark | $7.263B | 0.00 |
| Insulet (PODD) | United States | $7.231B | 526.83 |
| Hill-Rom Holdings (HRC) | United States | $7.018B | 21.28 |
| Perrigo (PRGO) | Ireland | $7.012B | 11.85 |
| Aurora Cannabis (ACB) | Canada | $6.936B | 68.40 |
| GN STORE NORD (GNNDY) | Denmark | $6.409B | 32.73 |
| Haemonetics (HAE) | United States | $6.251B | 51.03 |
| ICU Medical (ICUI) | United States | $5.188B | 30.95 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.991B | 0.00 |
| Neogen (NEOG) | United States | $3.334B | 54.21 |
| NuVasive (NUVA) | United States | $3.016B | 24.63 |
| Hutchison China MediTech (HCM) | China | $2.777B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $2.746B | 0.00 |
| National Vision Holdings (EYE) | United States | $2.480B | 52.83 |
| Quidel (QDEL) | United States | $2.268B | 23.54 |
| Aphria (APHA) | $1.604B | 0.00 | |
| Cardiovascular Systems (CSII) | United States | $1.543B | 886.40 |
| Phibro Animal Health (PAHC) | United States | $1.216B | 18.22 |
| AtriCure (ATRC) | United States | $1.203B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.174B | 24.93 |
| NanoString Technologies (NSTG) | United States | $1.114B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $1.097B | 29.13 |
| PetIQ (PETQ) | United States | $1.015B | 24.66 |
| Quanterix (QTRX) | United States | $0.779B | 0.00 |
| Cerus (CERS) | United States | $0.761B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.750B | 21.04 |
| MacroGenics (MGNX) | United States | $0.717B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.681B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.598B | 28.97 |
| OraSure Technologies (OSUR) | United States | $0.530B | 24.40 |
| Surmodics (SRDX) | United States | $0.527B | 76.59 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.499B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.492B | 15.04 |
| BioLife Solutions (BLFS) | United States | $0.330B | 103.12 |
| Utah Medical Products (UTMD) | United States | $0.321B | 22.20 |
| Vapotherm (VAPO) | United States | $0.320B | 0.00 |
| Zynex (ZYXI) | United States | $0.251B | 25.77 |
| Cytosorbents (CTSO) | United States | $0.242B | 0.00 |
| Bovie Medical (APYX) | United States | $0.214B | 0.00 |
| Chimerix (CMRX) | United States | $0.188B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.174B | 0.00 |
| United Health Products (UEEC) | United States | $0.170B | 0.00 |
| Owens & Minor (OMI) | United States | $0.166B | 3.52 |
| Fonar (FONR) | United States | $0.142B | 7.49 |
| Female Health (VERU) | United States | $0.134B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.103B | 0.00 |
| United-Guardian (UG) | United States | $0.092B | 20.16 |
| InfuSystems Holdings (INFU) | United States | $0.090B | 0.00 |
| Surface Oncology (SURF) | United States | $0.076B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.067B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.053B | 18.33 |
| MRI INTERVENTNS (MRIC) | United States | $0.052B | 0.00 |
